High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease.
Since the pioneering work of John Gofman in the 1950s, our understanding of high density lipoprotein cholesterol (HDL-C) and its relationship to coronary heart disease (CHD) has grown substantially. Numerous clinical trials since the Framingham Study in 1977 have demonstrated an inverse relationship between HDL-C and one's risk of developing CHD. Over the past two decades, preclinical research has gained further insight into the nature of HDL-C metabolism, specifically regarding the ability of HDL-C to promote reverse cholesterol transport (RCT). Recent attempts to harness HDL's ability to enhance RCT have revealed the complexity of HDL-C metabolism. This review provides a detailed update on HDL-C as an evolving therapeutic target in the management of cardiovascular disease.
Kapur
Navin K
NK
Division of Cardiology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA. nkapur@tufts-NEMC.org
Ashen
Dominique
D
Blumenthal
Roger S
RS
D000818:Animals; D002318:Cardiovascular Diseases / Q000178:diet therapy / Q000188:drug therapy* / Q000378:metabolism; D008076:Cholesterol, HDL / Q000187:drug effects* / Q000378:metabolism; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D012307:Risk Factors; D016540:Smoking Cessation
D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents